Cargando…
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Drug survival of biologics represents their real-world effectiveness and safety. We conducted a meta-analysis of real-world evidence on the drug survival of biologics in treating psoriasis. We searched the PubMed, CENTRAL, and EMBASE databases from inception to 7th October 2017 for studies reporting...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207685/ https://www.ncbi.nlm.nih.gov/pubmed/30375427 http://dx.doi.org/10.1038/s41598-018-34293-y |
_version_ | 1783366561664335872 |
---|---|
author | Lin, Pei-Tzu Wang, Shu-Hui Chi, Ching-Chi |
author_facet | Lin, Pei-Tzu Wang, Shu-Hui Chi, Ching-Chi |
author_sort | Lin, Pei-Tzu |
collection | PubMed |
description | Drug survival of biologics represents their real-world effectiveness and safety. We conducted a meta-analysis of real-world evidence on the drug survival of biologics in treating psoriasis. We searched the PubMed, CENTRAL, and EMBASE databases from inception to 7th October 2017 for studies reporting the annual drug survival for at least 1 year. Two authors independently screened and selected relevant studies, and assessed their risk of bias. A third author was available for arbitrating discrepancies. We conducted a random-effects model meta-analysis to obtain the respective pooled drug survival from year 1 to 4. We conducted subgroup analysis on biologic-naïve subjects, discontinuation for loss of efficacy and adverse effects. We included 37 studies with 32,631 subjects. The drug survival for all biologics decreased with time, dropping from 66% at year 1 to 41% at year 4 for etanercept, from 69% to 47% for adalimumab, from 61% to 42% for infliximab, and from 82% to 56% for ustekinumab. Ustekinumab was associated with the highest drug survival in all and biologic-naïve subjects. Etanercept was associated with the lowest drug survival and was most commonly discontinued for loss of efficacy. Infliximab was most frequently associated with discontinuation for adverse effects. Clinicians may use this study as a reference in treating psoriasis. |
format | Online Article Text |
id | pubmed-6207685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62076852018-11-01 Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence Lin, Pei-Tzu Wang, Shu-Hui Chi, Ching-Chi Sci Rep Article Drug survival of biologics represents their real-world effectiveness and safety. We conducted a meta-analysis of real-world evidence on the drug survival of biologics in treating psoriasis. We searched the PubMed, CENTRAL, and EMBASE databases from inception to 7th October 2017 for studies reporting the annual drug survival for at least 1 year. Two authors independently screened and selected relevant studies, and assessed their risk of bias. A third author was available for arbitrating discrepancies. We conducted a random-effects model meta-analysis to obtain the respective pooled drug survival from year 1 to 4. We conducted subgroup analysis on biologic-naïve subjects, discontinuation for loss of efficacy and adverse effects. We included 37 studies with 32,631 subjects. The drug survival for all biologics decreased with time, dropping from 66% at year 1 to 41% at year 4 for etanercept, from 69% to 47% for adalimumab, from 61% to 42% for infliximab, and from 82% to 56% for ustekinumab. Ustekinumab was associated with the highest drug survival in all and biologic-naïve subjects. Etanercept was associated with the lowest drug survival and was most commonly discontinued for loss of efficacy. Infliximab was most frequently associated with discontinuation for adverse effects. Clinicians may use this study as a reference in treating psoriasis. Nature Publishing Group UK 2018-10-30 /pmc/articles/PMC6207685/ /pubmed/30375427 http://dx.doi.org/10.1038/s41598-018-34293-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Lin, Pei-Tzu Wang, Shu-Hui Chi, Ching-Chi Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence |
title | Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence |
title_full | Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence |
title_fullStr | Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence |
title_full_unstemmed | Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence |
title_short | Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence |
title_sort | drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207685/ https://www.ncbi.nlm.nih.gov/pubmed/30375427 http://dx.doi.org/10.1038/s41598-018-34293-y |
work_keys_str_mv | AT linpeitzu drugsurvivalofbiologicsintreatingpsoriasisametaanalysisofrealworldevidence AT wangshuhui drugsurvivalofbiologicsintreatingpsoriasisametaanalysisofrealworldevidence AT chichingchi drugsurvivalofbiologicsintreatingpsoriasisametaanalysisofrealworldevidence |